ACADIA Pharmaceuticals (NasdaqGS:ACAD) - Share price, News & Analysis

ACAD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

ACAD Overview

Rewards

Trading at 89.5% below our estimate of its fair value

Earnings are forecast to grow 77.59% per year

Risk Analysis

No risks detected for ACAD from our risk checks.

Price History & Performance

Summary of all time highs, changes and price drops for ACADIA Pharmaceuticals
Historical stock prices
Current Share Price	US$16.70
52 Week High	US$15.68
52 Week Low	US$57.46
Beta	0.65
1 Month Change	3.47%
3 Month Change	-35.84%
1 Year Change	-60.63%
3 Year Change	-17.20%
5 Year Change	-52.26%
Change since IPO	149.25%

Recent News & Updates

Jul 30

Acadia's Essential Questions Heading Into Q2 2021 Earnings

So far Acadia has had a rough H1 2021; whether or not things will get better during H2 is the biggest question. Its prognosis depends in part on assessing the cause for Acadia's last minute unexpected and unexplained CRL, bureaucratic bungling by the FDA, management action, or questionable trial design. One plausible possibility is that the trial design included a problem issue from the start that was not recognized until the very end. Acadia reports Q2 2021 earnings on 08/04/2021 after a mixed string of earnings reports with muted expectations.

Shareholder Returns

	ACAD	US Biotechs	US Market
7D	3.8%	0.5%	-0.6%
1Y	-60.6%	25.9%	33.8%

Return vs Industry: ACAD underperformed the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: ACAD underperformed the US Market which returned 33.8% over the past year.

Price Volatility

Is ACAD's price volatile compared to industry and market?
ACAD volatility
ACAD Beta	0.65
Industry Beta	1.03
Market Beta	1

Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ACAD's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1993	610	Steve Davis	https://www.acadia-pharm.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder.

ACADIA Pharmaceuticals Fundamentals Summary

How do ACADIA Pharmaceuticals's earnings and revenue compare to its market cap?
ACAD fundamental statistics
Market Cap	US$2.68b
Earnings (TTM)	-US$261.74m
Revenue (TTM)	US$463.36m

5.8x

P/S Ratio

-10.2x

P/E Ratio

Is ACAD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACAD income statement (TTM)
Revenue	US$463.36m
Cost of Revenue	US$282.79m
Gross Profit	US$180.57m
Expenses	US$442.31m
Earnings	-US$261.74m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.64
Gross Margin	38.97%
Net Profit Margin	-56.49%
Debt/Equity Ratio	0%

How did ACAD perform over the long term?

See historical performance and comparison

Valuation

Is ACADIA Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ACAD ($16.7) is trading below our estimate of fair value ($158.48)

Significantly Below Fair Value: ACAD is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: ACAD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ACAD is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACAD's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ACAD is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (3.2x).

Future Growth

How is ACADIA Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

77.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ACAD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACAD's is expected to become profitable in the next 3 years.

Revenue vs Market: ACAD's revenue (28.3% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ACAD's revenue (28.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACAD's Return on Equity is forecast to be low in 3 years time (13.4%).

Past Performance

How has ACADIA Pharmaceuticals performed over the past 5 years?

0.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ACAD is currently unprofitable.

Growing Profit Margin: ACAD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ACAD is unprofitable, but has reduced losses over the past 5 years at a rate of 0.8% per year.

Accelerating Growth: Unable to compare ACAD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).

Return on Equity

High ROE: ACAD has a negative Return on Equity (-46.34%), as it is currently unprofitable.

Financial Health

How is ACADIA Pharmaceuticals's financial position?

Financial Position Analysis

Short Term Liabilities: ACAD's short term assets ($645.7M) exceed its short term liabilities ($95.3M).

Long Term Liabilities: ACAD's short term assets ($645.7M) exceed its long term liabilities ($64.3M).

Debt to Equity History and Analysis

Debt Level: ACAD is debt free.

Reducing Debt: ACAD has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACAD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACAD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACAD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACAD's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure

CEO

Steve Davis (60 yo)

6yrs

Tenure

US$7,763,187

Compensation

Mr. Stephen R. Davis, also known as Steve, J.D., serves as the Director at Heron Therapeutics Inc. since October 2019. He has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since Septembe...

CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD7.76M) is above average for companies of similar size in the US market ($USD5.27M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ACAD's management team is considered experienced (2.7 years average tenure).

Board Members

Experienced Board: ACAD's board of directors are considered experienced (5.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2021/09/18 22:13
End of Day Share Price	2021/09/17 00:00
Earnings	2021/06/30
Annual Earnings	2020/12/31

Market Cap

7D

1Y

Updated

Data